Recombinant CD79a Antibody [IGA/1790R]

IgG, k

Aliquot and Store at 2-8˚ C. Avoid freez-thaw cycles.

A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.

Recombinant

Protein A affinity chromatography

PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Amino acids 202-216 (GTYQDVGSLNIADVQ) were used as the immunogen for the recombinant CD79a antibody.

CD79a molecule, immunoglobulin-associated alpha

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.